Skip to main content

SAB Biotherapeutics, Inc.

corporate_fare Company Profile

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SABS - Latest Insights

SABS
Apr 22, 2026, 8:13 AM EDT
Filing Type: 8-K
Importance Score:
8
SABS
Mar 23, 2026, 4:25 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
SABS
Mar 18, 2026, 8:28 PM EDT
Filing Type: 8-K
Importance Score:
8
SABS
Mar 18, 2026, 8:26 PM EDT
Filing Type: 424B5
Importance Score:
8
SABS
Mar 17, 2026, 10:46 PM EDT
Source: GlobeNewswire
Importance Score:
8
SABS
Mar 17, 2026, 4:00 PM EDT
Filing Type: 424B5
Importance Score:
7
SABS
Mar 11, 2026, 4:43 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
SABS
Mar 10, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
7
SABS
Mar 09, 2026, 5:16 PM EDT
Source: GlobeNewswire
Importance Score:
8
SABS
Mar 09, 2026, 5:10 PM EDT
Filing Type: 10-K
Importance Score:
8
SABS
Jan 12, 2026, 4:47 PM EST
Filing Type: 8-K
Importance Score:
8
SABS
Jan 07, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8